nu6102 and dinaciclib

nu6102 has been researched along with dinaciclib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Caldon, EC; Tadesse, S; Tilley, W; Wang, S	1
Gucký, T; Heger, T; Jansa, J; Jorda, R; Kryštof, V; Lyčka, A; Pachl, P; Peřina, M; Řezáčová, P; Řezníčková, E; Škerlová, J	1

Reviews

1 review(s) available for nu6102 and dinaciclib

Article	Year
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. Journal of medicinal chemistry, 2019, 05-09, Volume: 62, Issue:9 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinase 2; Drug Design; Humans; Neoplasms; Protein Binding; Protein Conformation; Protein Kinase Inhibitors	2019

Other Studies

1 other study(ies) available for nu6102 and dinaciclib

Article	Year
Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure. European journal of medicinal chemistry, 2021, Apr-15, Volume: 216 Topics: Antineoplastic Agents; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Humans; Hydrogen Bonding; Imidazoles; Molecular Dynamics Simulation; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship	2021

Article

Year

Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.

European journal of medicinal chemistry, 2021, Apr-15, Volume: 216

Topics: Antineoplastic Agents; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Humans; Hydrogen Bonding; Imidazoles; Molecular Dynamics Simulation; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship

2021